N/A
N=60
Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
Breast Cancer
Bottom Line
View on ClinicalTrials.gov: NCT03123263 ↗Enrolled (actual)
60
Serious AEs
3.3%
Results posted
Sep 2019
Primary outcome: Primary: LVEF — 65.4; 64.7; 62.2 percentage of blood in left ventricle — p=<0.0005
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
- Primary completion
- Feb 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY LVEF |
65.4; 64.7; 62.2 | <0.0005 sig |
| SECONDARY Number of Participants Hospitalized for Cardiac Issues. |
— | — |
Summary
This study retrospectively looks at changes in Echocardiographic parameters while using transtuzumab
Eligibility Criteria
Inclusion Criteria
- Stage 1,2,3 breast cancer
- Her2+
Exclusion Criteria
- Stage 4 cancer
Data sourced from ClinicalTrials.gov (NCT03123263). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.